The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Dec. 17, 2019

Filed:

Nov. 27, 2015
Applicant:

Celltrion Inc., Incheon, KR;

Inventors:

Joon Sun Yoon, Incheon, KR;

Hwa Jin Lee, Ulsan, KR;

Kye Sook Yi, Incheon, KR;

Cheol Min Kim, Bucheon-si, KR;

Byung Pil Lim, Seoul, KR;

Shin Jae Chang, Incheon, KR;

Seung Suh Hong, Seoul, KR;

Assignee:

CELLTRION, Inc., Incheon, KR;

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/08 (2006.01); A61K 39/12 (2006.01); A61K 39/29 (2006.01); A61K 39/395 (2006.01); C07K 14/02 (2006.01); A61K 38/16 (2006.01); C12N 15/11 (2006.01); C12N 15/63 (2006.01);
U.S. Cl.
CPC ...
A61K 39/292 (2013.01); A61K 38/162 (2013.01); A61K 39/29 (2013.01); A61K 39/395 (2013.01); C07K 14/02 (2013.01); C07K 16/08 (2013.01); C07K 16/082 (2013.01); C07K 2317/34 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); C12N 15/11 (2013.01); C12N 15/63 (2013.01); C12N 2710/24261 (2013.01);
Abstract

The present invention relates to an epitope specific to hepatitis B virus surface antigen and a binding molecule binding to the same for neutralizing hepatitis B virus. Since the epitope provided by the present invention is produced by forming a three-dimensional structure and does not comprise a determinant, by which escape mutation is induced against an administration of existing vaccines or HBIg, a composition comprising an antibody biding to the epitope or a vaccine composition comprising the epitope has a very low possibility of causing a decrease in efficacy due to escape mutation. Therefore, such an antibody or vaccine composition can be very effectively used in prevention and/or treatment of HBV.


Find Patent Forward Citations

Loading…